Generation Bio Co GBIO.OQ GBIO.O is expected to show a fall in quarterly revenue when it reports results on March 4 (estimated) for the period ending December 31 2024
The Cambridge Massachusetts-based company is expected to report a 13.1% decrease in revenue to $2.5 million from $2.88 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Generation Bio Co is for a loss of 30 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Generation Bio Co is $7.00, above its last closing price of $0.54.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.28 | -0.28 | -0.23 | Beat | 18.6 |
Jun. 30 2024 | -0.29 | -0.28 | -0.31 | Missed | -11.3 |
Mar. 31 2024 | -0.40 | -0.41 | -1.12 | Missed | -174.4 |
Dec. 31 2023 | -0.44 | -0.45 | -0.53 | Missed | -18.2 |
Sep. 30 2023 | -0.50 | -0.50 | -0.43 | Beat | 14.9 |
Jun. 30 2023 | -0.50 | -0.50 | -0.47 | Beat | 5.4 |
Mar. 31 2023 | -0.45 | -0.46 | -0.53 | Missed | -14.2 |
Dec. 31 2022 | -0.58 | -0.58 | -0.55 | Beat | 5 |
This summary was machine generated February 28 at 11:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。